NCT07374848
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 16 words
- Trial sites expanded: 8 → 12 locations
- Minor Study sites: 6 to 8v7
- Minor Study sites: 5 to 6v5
- Minor Trial sites expanded: 2 → 5 locations
- Start date changed from estimate of Mar 2026 to Mar 2, 2026
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Dose Limiting Toxicities
Timeframe: 1 cycle of study treatment (each cycle is 21 days)
Incidence of Treatment Emergent Adverse Events
Timeframe: 36 months
Incidence of Serious adverse events
Timeframe: 36 months
Number of participants with clinical laboratory abnormalities
Timeframe: 36 months
Number of participants with vital sign abnormalities
Timeframe: 36 months
Number of participants with electrocardiogram (ECG) abnormalities
Timeframe: 36 months
Secondary (6)
ORR per RECIST 1.1
Duration of Response per RECIST 1.1
PFS per RECIST 1.1
DCR per RECIST 1.1
PK characteristics of ZL-6201 (ADC conjugate), total antibody
Show 1 moreShow less
PK characteristics of ZL-6201 (ADC conjugate), unconjugated payloads
Arms and interventions
ZL-6201Experimental
ZL-6201 as a single agent
Drugs: ZL-6201
Sites
12 sites in 2 countries
United States 7, China 5